Legacy CG LLC Buys 14,257 Shares of AbbVie Inc. $ABBV

Legacy CG LLC lifted its stake in AbbVie Inc. (NYSE:ABBV) by 105.0% in the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 27,838 shares of the company’s stock after buying an additional 14,257 shares during the period. AbbVie comprises 1.8% of Legacy CG LLC’s portfolio, making the stock its 25th biggest holding. Legacy CG LLC’s holdings in AbbVie were worth $6,446,000 as of its most recent filing with the SEC.

A number of other institutional investors have also added to or reduced their stakes in the company. Norges Bank bought a new stake in shares of AbbVie during the second quarter valued at approximately $4,288,200,000. Laurel Wealth Advisors LLC increased its holdings in AbbVie by 18,384.4% in the 2nd quarter. Laurel Wealth Advisors LLC now owns 5,705,964 shares of the company’s stock valued at $1,059,141,000 after buying an additional 5,675,095 shares during the period. Assenagon Asset Management S.A. raised its stake in shares of AbbVie by 550.9% in the 2nd quarter. Assenagon Asset Management S.A. now owns 4,332,054 shares of the company’s stock valued at $804,116,000 after buying an additional 3,666,521 shares in the last quarter. Vanguard Group Inc. lifted its holdings in shares of AbbVie by 1.9% during the 2nd quarter. Vanguard Group Inc. now owns 177,298,707 shares of the company’s stock worth $32,910,186,000 after acquiring an additional 3,380,842 shares during the period. Finally, Kingstone Capital Partners Texas LLC acquired a new stake in shares of AbbVie during the 2nd quarter valued at about $581,817,000. 70.23% of the stock is owned by institutional investors and hedge funds.

Key Headlines Impacting AbbVie

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Berenberg Bank raised AbbVie to a Buy, providing an analyst-driven demand tailwind that can support near-term share gains. AbbVie (ABBV) Receives a Buy from Berenberg Bank
• Positive Sentiment: Multiple reports (WSJ/Reuters) said AbbVie was in advanced talks to acquire Revolution Medicines, fueling takeover speculation that typically lifts a buyer’s stock ahead of any deal announcement. AbbVie Near Deal for Revolution Medicines AbbVie in talks to buy biotech Revolution Medicines, WSJ reports
• Positive Sentiment: AbbVie expanded its oncology pipeline with a first‑in‑human ABBV‑901 trial in ovarian cancer — a pipeline development that supports longer‑term growth narratives beyond legacy assets. AbbVie Expands Ovarian Cancer Pipeline With New ABBV‑901 Trial
• Neutral Sentiment: Revolution Medicines shares jumped on the takeover rumors (market context), which contributed to intraday volatility in AbbVie-related news flow but doesn’t change AbbVie’s fundamentals unless a deal is announced. Revolution Medicines stock surges over 20%
• Neutral Sentiment: AbbVie scheduled its full‑year and fourth‑quarter 2025 earnings release and conference call for Feb. 4 — a routine event that will be the next formal opportunity for management to set expectations and move the stock. AbbVie to Host Full-Year and Fourth-Quarter 2025 Earnings Conference Call
• Neutral Sentiment: UBS reiterated a Hold rating, highlighting a balanced risk/reward given AbbVie’s premium valuation versus long-duration growth — a reminder that some analysts see limited upside from here. AbbVie: Premium Valuation… Hold Rating
• Negative Sentiment: AbbVie updated guidance: Q4 2025 EPS 3.320–3.360 and FY2025 EPS 10.610–10.650, each nudging slightly under consensus — a conservative tilt that can cap upside and explain some profit‑taking. (Company guidance released 1/8/2026)
• Negative Sentiment: After takeover reports, AbbVie publicly denied talks to buy Revolution Medicines, which may roll back some of the acquisition-driven rally and increase short-term volatility. Abbvie denies WSJ report of talks to buy Revolution Medicines
• Negative Sentiment: Competitive pressure: J&J’s Tremfya outspent AbbVie’s Skyrizi on TV ads through December, underscoring intense competition in immunology that can pressure market share and pricing over time. Tremfya outstrips Skyrizi in TV ad spend

Analysts Set New Price Targets

Several research analysts recently issued reports on ABBV shares. Berenberg Bank raised shares of AbbVie from a “hold” rating to a “buy” rating and increased their price target for the stock from $170.00 to $270.00 in a research report on Wednesday, September 17th. Evercore ISI increased their target price on AbbVie from $207.00 to $222.00 and gave the stock an “outperform” rating in a report on Monday, September 22nd. Wall Street Zen lowered AbbVie from a “strong-buy” rating to a “buy” rating in a research note on Saturday, January 3rd. Guggenheim upped their price target on AbbVie from $227.00 to $242.00 and gave the company a “buy” rating in a research report on Monday, October 20th. Finally, DZ Bank cut AbbVie from a “buy” rating to a “hold” rating and set a $237.00 price objective for the company. in a report on Tuesday, November 4th. Three investment analysts have rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and eight have given a Hold rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $246.89.

AbbVie Stock Performance

Shares of ABBV opened at $233.65 on Thursday. The company has a market cap of $412.95 billion, a price-to-earnings ratio of 177.01, a PEG ratio of 0.94 and a beta of 0.36. The stock has a fifty day moving average price of $226.63 and a two-hundred day moving average price of $214.80. AbbVie Inc. has a 52-week low of $164.39 and a 52-week high of $244.81.

AbbVie (NYSE:ABBV) last announced its earnings results on Friday, October 31st. The company reported $1.86 earnings per share for the quarter, beating analysts’ consensus estimates of $1.77 by $0.09. AbbVie had a return on equity of 3,216.47% and a net margin of 4.00%.The company had revenue of $15.78 billion during the quarter, compared to analyst estimates of $15.58 billion. During the same period last year, the company posted $3.00 earnings per share. The firm’s quarterly revenue was up 9.1% compared to the same quarter last year. AbbVie has set its Q4 2025 guidance at 3.320-3.360 EPS. As a group, research analysts predict that AbbVie Inc. will post 12.31 EPS for the current fiscal year.

AbbVie Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, February 17th. Investors of record on Friday, January 16th will be given a $1.73 dividend. This is a boost from AbbVie’s previous quarterly dividend of $1.64. The ex-dividend date is Friday, January 16th. This represents a $6.92 annualized dividend and a yield of 3.0%. AbbVie’s dividend payout ratio is presently 496.97%.

AbbVie Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.